According to a market report by Lucintel, the future of the global adenovirus vaccine market looks promising with opportunities in the research and academic, laboratories, and pharmaceutical & biotechnology markets. The global adenovirus vaccine market is expected to reach an estimated $1.4 billion by 2030 with a CAGR of 7.5% from 2024 to 2030. The major drivers for this market are the rapidly increasing need for vaccinations in cancer gene therapies and surge in vaccination demand from pharmaceutical companies.

A more than 150 – page report is developed to understand Trends, opportunity and forecast in adenovirus vaccine market to 2030 by type (type 4 vaccine and type 7 vaccine), application (research and academic, laboratories, and pharmaceutical & biotechnology), and region (North America, Europe, Asia Pacific, and the Rest of the World).

In this market, type 4 and type 7 vaccine are the major segments of adenovirus vaccine market by type. Lucintel forecasts that type 7 vaccine is expected to witness higher growth over the forecast period due to its affordability and ability to instantly confer immunity.

Within this market, research and academic is expected to witness highest growth over the forecast period.

North America is expected to witness highest growth over the forecast period due to due to the high prevalence of adenovirus infection and continuous population growth in the region.

Novasep, Charles River Laboratories, Uniqure, Waisman Biomanufacturing, Creative-Biogene, Aldevron, Addgene, Thermo Fisher Scientific, Fujifilm Corporation, and Spark Therapeutics are the major suppliers in the adenovirus vaccine market.

 This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or write us at helpdesk@lucintel.com